Treatment of relapsing multiple sclerosis in Hungary - consensus recommendation from the Hungarian neuroimmunology society.
Consensus
Multiple sclerosis
Recommendation
Treatment
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
04
04
2023
accepted:
18
06
2023
medline:
10
7
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS) from disability accumulation and progression. Different countries have different reimbursement policies resulting in inequalities in patient care among geographical regions. Access to anti-CD20 therapies for relapsing MS is restricted in Hungary because therapy of individual cases only is reimbursed. In the light of the latest research and national guidelines, 17 Hungarian MS experts agreed on 8 recommendations regarding relapsing pwMS using the Delphi round method. Strong agreement (> 80%) was achieved in all except one recommendation after three rounds, which generated a fourth Delphi round. The experts agreed on treatment initiation, switch, follow-up and discontinuation, as well as on special issues such as pregnancy, lactation, elderly population, and vaccination. Well-defined national consensus protocols may facilitate dialogue between policymakers and healthcare professionals and thus contribute to better patient care in the long run.
Identifiants
pubmed: 37420270
doi: 10.1186/s13023-023-02789-0
pii: 10.1186/s13023-023-02789-0
pmc: PMC10329288
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183Informations de copyright
© 2023. The Author(s).
Références
J Comp Eff Res. 2020 Dec;9(18):1255-1274
pubmed: 33090003
Neurology. 2021 Feb 2;96(5):e783-e797
pubmed: 33372028
Croat Med J. 2022 Aug 31;63(4):379-388
pubmed: 36046935
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Croat Med J. 2018 Apr 30;59(2):65-70
pubmed: 29740990
JAMA Neurol. 2021 Oct 1;78(10):1197-1204
pubmed: 34398221
J Neurol. 2022 Mar;269(3):1670-1677
pubmed: 34626224
Mult Scler. 2010 May;16(5):520-5
pubmed: 20215479
Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648
pubmed: 34422112
PLoS One. 2020 Jul 27;15(7):e0236432
pubmed: 32716953
Neurology. 2018 Apr 24;90(17):789-800
pubmed: 29686117
Neurology. 2020 Aug 25;95(8):e1041-e1051
pubmed: 32636328
PLoS One. 2022 Mar 3;17(3):e0264328
pubmed: 35239686
JAMA Neurol. 2015 Feb;72(2):152-8
pubmed: 25531931
Ann Clin Transl Neurol. 2023 Mar;10(3):302-311
pubmed: 36728340
Mult Scler. 2020 Dec;26(14):1807-1808
pubmed: 33174499
Can J Neurol Sci. 2020 Jul;47(4):437-455
pubmed: 32654681
Nat Rev Neurol. 2019 May;15(5):287-300
pubmed: 30940920
Lancet Neurol. 2023 Apr;22(4):350-366
pubmed: 36931808
Neurology. 2016 Jul 12;87(2):134-40
pubmed: 27306626
JAMA. 2019 Jan 15;321(2):175-187
pubmed: 30644981
Mult Scler. 2009 Jul;15(7):848-53
pubmed: 19542263
Mult Scler. 2018 Feb;24(2):96-120
pubmed: 29353550
Brain Behav. 2020 May;10(5):e01598
pubmed: 32196981
Mult Scler Relat Disord. 2021 Aug;53:103076
pubmed: 34161898